{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:48:50Z","timestamp":1788922130694,"version":"build-2803163510"},"reference-count":55,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The primary objective of this study was to evaluate opioid and barbiturate utilization before and after the first prescription of the calcitonin gene\u2013related peptide receptor antagonist rimegepant in individuals with migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although not recommended in migraine treatment guidelines, opioids and barbiturates are often prescribed for the acute treatment of migraine, despite the risks of dependence and harm. Initiating a migraine\u2010specific acute treatment might reduce the use of opioids and barbiturates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study among adults in the United States with migraine and a first prescription for rimegepant (fill quantity of eight tablets, indicative of acute treatment) was based on administrative claims data from the IQVIA PharMetrics Plus longitudinal health plan database (September 1, 2019, through March 31, 2023). For opioids and butalbital (separately), number of prescription fills and average dispensed amounts (as morphine milligram equivalents [MME] and milligrams [mg], respectively) were assessed in the 180\u2009days preceding (pre\u2010index) and the 180\u2009days following (post\u2010index) rimegepant initiation. Subgroup analyses included individuals using \u2265\u20091 preventive treatment, and individuals with problematic opioid use (\u2265\u20093 opioid prescriptions and\/or MME in the fourth quartile).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 1928 opioid users, rimegepant initiation was associated with a significant difference in opioid prescription fills (median [interquartile range (IQR)] 2 [1\u20135] pre\u2010index vs. 1 [0\u20135] post\u2010index,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and average dispensed MME (25 [17.5\u201337.5] pre\u2010index vs. 14 [0\u201330] post\u2010index,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and 740 users (38.4%) discontinued opioids. Among 873 butalbital users, rimegepant initiation was associated with a significant difference in butalbital prescription fills (median [IQR] 2 [1\u20134] pre\u2010index vs. 1 [0\u20133] post\u2010index,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and average dispensed mg (200 [100\u2013300] pre\u2010index vs. 25 [0\u2013187.5] post\u2010index,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and 422 users (48.3%) discontinued opioids. Rimegepant initiation was associated with reduction of opioid and butalbital utilization in the subgroups using preventive treatment, and reduction of opioid utilization in the subgroup with problematic opioid use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rimegepant initiation was associated with reductions in utilization of opioids and butalbital, including in individuals using preventive treatment for migraine, and with reduction of opioid utilization in individuals with problematic opioid use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.15004","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T08:24:22Z","timestamp":1752308662000},"page":"835-845","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States"],"prefix":"10.1111","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5657-2206","authenticated-orcid":false,"given":"Noah","family":"Rosen","sequence":"first","affiliation":[{"name":"Northwell Health  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D UK Ltd  Tadworth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hygge Blakeman","sequence":"additional","affiliation":[{"name":"Pfizer  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Dai","sequence":"additional","affiliation":[{"name":"Pfizer  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Abraham","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D UK Ltd  Tadworth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Leroue","sequence":"additional","affiliation":[{"name":"Pfizer  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Brown","sequence":"additional","affiliation":[{"name":"Pfizer  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"key":"e_1_2_12_2_1","article-title":"The opioid epidemic: a review of the contributing factors, negative consequences, and best practices","volume":"15","author":"Judd D","year":"2023","journal-title":"Cureus"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32229-9"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/15360288.2016.1173762"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.02050.x"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-022-00200-0"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1941874412439583"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.11.1272"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14018"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411398400"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000001037"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03612.x"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241235139"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2012.02140.x"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000335946.53860.1d"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00509-5"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828aab14"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2019.07.009"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2020.42544"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.11.025"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14238"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.5847\/wjem.j.1920-8642.2017.03.002"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13275"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419835465"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414539055"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14071"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12645"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01819.x"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.01189.x"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-002-0012-y"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413500727"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S453806"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00126-6"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32544-7"},{"issue":"18","key":"e_1_2_12_40_1","article-title":"Reduction in opioid prescription fills and morphine milligram equivalent dispensed following initiation of Nurtec ODT treatment \u2013 a real world administrative claims study (S31.010)","volume":"98","author":"Mohajer A","year":"2022","journal-title":"Neurology"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14523"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16616"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.23.11.1169"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2020.12.056"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417716933"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14523"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.1167"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905307"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14068"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.21060"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.613372"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-823357-3.00013-6"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110608"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61628-9"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20130332"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000280"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.15004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.15004","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.15004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:24:00Z","timestamp":1775114640000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.15004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/head.15004"],"URL":"https:\/\/doi.org\/10.1111\/head.15004","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"2024-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}